InnoCare (诺诚健华) IPO: Bifurcated Book, Update of Our View
InnoCare launched the book building on March 11th to raise up to USD 288 million to list in Hong Kong. Book building will end on March 16...
455 Views
InnoCare Pharma IPO: Valuation Easy to Swallow
InnoCare Pharma Ltd (9969 HK) is a pre-revenue biotech company with a focus on research and development, manufacturing and commercialisation of...
472 Views
A Bottom Has Been Established; Possible Retest?
In today’s report we outline our belief that the combination of extreme oversold conditions and several key sectors/industries holding above major...
371 Views
InnoCare Pharma IPO Initiation: Promising Prognosis
InnoCare Pharma Ltd (1576300D CH) is a pre-revenue biotech company with a focus on research and development, manufacturing and commercialisation of...
390 Views
Akesobio (康方生物) Pre-IPO: Late in the PD-1 Game but Products Are Promising
Akesobio is a clinical-stage biopharmaceutical company with a focus on developing biologics drugs for oncology and autoimmune. The company plans to...
614 Views